A detailed history of Reynders Mc Veigh Capital Management, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Reynders Mc Veigh Capital Management, LLC holds 36,267 shares of ABBV stock, worth $7.09 Million. This represents 0.35% of its overall portfolio holdings.

Number of Shares
36,267
Previous 37,451 3.16%
Holding current value
$7.09 Million
Previous $6.82 Million 8.8%
% of portfolio
0.35%
Previous 0.39%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$154.79 - $180.76 $183,271 - $214,019
-1,184 Reduced 3.16%
36,267 $6.22 Million
Q1 2024

May 07, 2024

BUY
$159.82 - $182.1 $5.99 Million - $6.82 Million
37,451 New
37,451 $6.82 Million
Q4 2023

Feb 07, 2024

SELL
$137.6 - $154.97 $100,860 - $113,593
-733 Reduced 1.76%
40,897 $6.34 Million
Q3 2023

Nov 09, 2023

SELL
$133.59 - $154.65 $130,250 - $150,783
-975 Reduced 2.29%
41,630 $6.21 Million
Q2 2023

Aug 09, 2023

BUY
$132.51 - $164.9 $190,549 - $237,126
1,438 Added 3.49%
42,605 $5.74 Million
Q1 2023

May 03, 2023

BUY
$144.61 - $166.54 $38,032 - $43,800
263 Added 0.64%
41,167 $6.56 Million
Q4 2022

Feb 10, 2023

SELL
$138.31 - $165.87 $382,565 - $458,796
-2,766 Reduced 6.33%
40,904 $6.61 Million
Q3 2022

Nov 08, 2022

SELL
$134.21 - $153.93 $230,304 - $264,143
-1,716 Reduced 3.78%
43,670 $5.86 Million
Q2 2022

Aug 05, 2022

SELL
$137.62 - $174.96 $174,226 - $221,499
-1,266 Reduced 2.71%
45,386 $6.95 Million
Q1 2022

May 11, 2022

SELL
$131.98 - $163.75 $209,716 - $260,198
-1,589 Reduced 3.29%
46,652 $7.56 Million
Q4 2021

Feb 11, 2022

SELL
$107.43 - $135.93 $4,189 - $5,301
-39 Reduced 0.08%
48,241 $6.53 Million
Q3 2021

Nov 15, 2021

BUY
$106.4 - $120.78 $32,558 - $36,958
306 Added 0.64%
48,280 $5.21 Million
Q2 2021

Aug 12, 2021

SELL
$105.21 - $117.21 $128,250 - $142,878
-1,219 Reduced 2.48%
47,974 $5.4 Million
Q1 2021

May 07, 2021

SELL
$102.3 - $112.62 $159,894 - $176,025
-1,563 Reduced 3.08%
49,193 $5.32 Million
Q4 2020

Feb 10, 2021

SELL
$80.49 - $108.67 $98,117 - $132,468
-1,219 Reduced 2.35%
50,756 $5.44 Million
Q3 2020

Oct 28, 2020

SELL
$85.91 - $100.83 $66,064 - $77,538
-769 Reduced 1.46%
51,975 $4.55 Million
Q2 2020

Aug 14, 2020

BUY
$73.37 - $98.18 $517,405 - $692,365
7,052 Added 15.43%
52,744 $5.18 Million
Q1 2020

May 13, 2020

SELL
$64.5 - $97.79 $102,168 - $154,899
-1,584 Reduced 3.35%
45,692 $3.48 Million
Q4 2019

Feb 14, 2020

BUY
$72.13 - $90.25 $1.04 Million - $1.3 Million
14,412 Added 43.85%
47,276 $4.19 Million
Q3 2019

Nov 08, 2019

BUY
$62.98 - $75.72 $198,764 - $238,972
3,156 Added 10.62%
32,864 $2.49 Million
Q2 2019

Aug 06, 2019

SELL
$65.7 - $83.98 $289,080 - $369,512
-4,400 Reduced 12.9%
29,708 $2.16 Million
Q1 2019

May 10, 2019

SELL
$77.14 - $90.79 $275,698 - $324,483
-3,574 Reduced 9.48%
34,108 $2.75 Million
Q4 2018

Feb 14, 2019

SELL
$77.85 - $96.01 $186,295 - $229,751
-2,393 Reduced 5.97%
37,682 $3.47 Million
Q3 2018

Nov 26, 2018

SELL
$88.91 - $98.84 $43,565 - $48,431
-490 Reduced 1.21%
40,075 $3.79 Million
Q2 2018

Aug 09, 2018

BUY
$89.78 - $106.23 $219,601 - $259,838
2,446 Added 6.42%
40,565 $3.76 Million
Q1 2018

Jul 26, 2018

BUY
$92.01 - $123.21 $3.18 Million - $4.25 Million
34,511 Added 956.51%
38,119 $3.61 Million
Q1 2018

May 03, 2018

SELL
$92.01 - $123.21 $3.26 Million - $4.37 Million
-35,481 Reduced 90.77%
3,608 $38.1 Million
Q4 2017

Feb 06, 2018

SELL
$89.56 - $98.21 $24,181 - $26,516
-270 Reduced 0.69%
39,089 $0
Q3 2017

Nov 09, 2017

SELL
$69.85 - $89.22 $1,397 - $1,784
-20 Reduced 0.05%
39,359 $3.5 Million
Q2 2017

Aug 14, 2017

BUY
N/A
39,379
39,379 $2.86 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $345B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Reynders Mc Veigh Capital Management, LLC Portfolio

Follow Reynders Mc Veigh Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Reynders Mc Veigh Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Reynders Mc Veigh Capital Management, LLC with notifications on news.